BioXcel Therapeutics, Inc.

Track this case

Case Number:

1:26-bk-11360

Court:

Delaware

Nature of Suit:

Firms

Companies

Sectors & Industries:

  1. October 05, 2026

    BioXcel's Ch. 11 Stayed Securities Settlement, Judge Says

    BioXcel Therapeutics' Chapter 11 filing paused a securities class action against it, a Delaware bankruptcy judge ruled Monday, after a federal court had pressed the life sciences group for a more detailed timeline on the final approval of a settlement in the litigation worth around $10 million.

  2. September 28, 2026

    Del. Judge OKs AI-Bolstered Drug Co.'s Ch. 11 Bid Procedures

    A Delaware bankruptcy judge granted his approval Monday to the bidding procedures proposed in the Chapter 11 case of a company that uses artificial intelligence to explore new uses for existing drugs.

  3. September 21, 2026

    Judge OKs Up To $3.2M In BioXcel Employee Ch. 11 Bonuses

    A Delaware bankruptcy judge approved employee retention and executive incentive payments that could total up to $3.2 million as AI-bolstered pharmaceutical group BioXcel works to sell its assets in Chapter 11.

  4. September 08, 2026

    Meet The Attorneys Guiding BioXcel Therapeutics' Ch. 11

    A group of attorneys from Young Conaway Stargatt & Taylor LLP and Cooley LLP is representing artificial intelligence-powered drug company BioXcel Therapeutics Inc. in its Chapter 11 case.

  5. September 01, 2026

    Catching Up With New Bankruptcy Case Action

    A winery in California's Napa Valley struggling to recover from wildfires hit Chapter 11. A vertical farming startup whose products were distributed by a dozen supermarket chains was forced to liquidate. And a military contractor foundered after losing a crucial government agency as a client.

  6. August 28, 2026

    AI-Bolstered Drug Co. Hits Ch. 11 With $105M Debt

    A company that uses artificial intelligence to explore new uses for existing drugs entered bankruptcy in Delaware with over $104 million in debt and a stalking horse bidder.